A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
← catalyst calendarNCT06878261 · readout in 937 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Amgen.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
990estimated
Sites
268
Countries
Argentina, Australia, Belgium +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-25 | actual | When the study began enrolling |
| Primary completion | 2029-03-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-05 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
- Biological: Tezepelumab
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualised rate of moderate or severe COPD exacerbations
measured Baseline up to 76 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed